Salubris leads Viracta venture round, gets Chinese rights to cancer therapy

Shenzhen Salubris Pharmaceuticals Co. Ltd. (SZSE:002294) led a series C round for Viracta Therapeutics Inc. (San Diego, Calif.) on Tuesday and gained Chinese rights to develop Viracta’s nanatinostat (VRx-3996) in combination with an antiviral to treat virus-associated malignancies.

Viracta CBO David Slack told BioCentury that the round is still open but has raised about $16.5 million to date. Slack said the round would close no later than 1Q19...